NCT01170442

Brief Summary

Vitamin D status has been negatively associated with the presence of type II DM and glycemic control. However, a cause-effect relationship between vitamin D deficiency and glycemic control has not been established. The investigators plan to conduct a double blind, randomized, placebo controlled trial on the effect of vitamin D supplementation on glycemic control in Type II DM.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for phase_3 diabetes-mellitus

Timeline
Completed

Started Dec 2011

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 25, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 27, 2010

Completed
1.3 years until next milestone

Study Start

First participant enrolled

December 1, 2011

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

April 1, 2015

Status Verified

March 1, 2015

Enrollment Period

2 years

First QC Date

July 25, 2010

Last Update Submit

March 31, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Area under the curve of HA1C.

    6 months

Secondary Outcomes (8)

  • Area under the curve for BP

    6 months

  • area under the curve of weight

    6 months

  • area under the curve for 25 OH vitamin D level

    6 months

  • area under the curve of fasting blood glucose

    6 months

  • area under the curve of 2 hour post breakfast glucose

    6 months

  • +3 more secondary outcomes

Study Arms (3)

vitamin D3 2000 IU

EXPERIMENTAL
Drug: vitamin D3 2000 IU

vitamin D3 5000 IU

EXPERIMENTAL
Drug: vitamin D3 5000 IU

Placebo

PLACEBO COMPARATOR
Drug: Placebo

Interventions

vitamin D3 2000 IU orally, daily for 6 months

Also known as: cholecalciferol
vitamin D3 2000 IU

vitamin D3 5000 IU orally, daily for 6 months

Also known as: cholecalciferol
vitamin D3 5000 IU

placebo orally, daily for six months

Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Type II diabetics living in Riyadh area who consume no more than one serving of milk/day
  • Do not take vitamin supplement
  • Habitually have less than 10 hour of sun exposure per week
  • Don't suffer from granulomatous conditions, liver disease, or kidney disease
  • Don't take anticonvulsants, barbiturates, or steroids.
  • Stable glycemic control (not more than 0.5% difference between current HA1c and a HA1c obtained 2-4 months earlier)
  • Current HA1c between 6.5 and 8%, and current total 25 OH vitamin D level between 10-30 nmol/L.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Faisal Specialist Hospital & Research Center

Riyadh, 11211, Saudi Arabia

Location

MeSH Terms

Conditions

Diabetes MellitusVitamin D Deficiency

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAvitaminosisDeficiency DiseasesMalnutritionNutrition Disorders

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Muhammad M Hammami, MD, PhD

    King Faisal Specialist Hospital & Research Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chairman, Department of Clinical Studies & Empirical Ethics

Study Record Dates

First Submitted

July 25, 2010

First Posted

July 27, 2010

Study Start

December 1, 2011

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

April 1, 2015

Record last verified: 2015-03

Locations